Pegylated liposomal doxorubicin (PLD) in heavily pretreated epithelial ovarian cancer patients

被引：0
|
作者：
Gorumlu, Gurbuz [1 ]
Kucukzeybek, Yuksel [1 ]
Karabulut, Bulent [1 ]
Terek, Mustafa C. [1 ]
Uslu, Ruchan [1 ]
Sanli, Ulus A. [1 ]
Akman, Levent [1 ]
Ozsaran, Aydin [1 ]
Dikmen, Yilmaz [1 ]
Goker, Erdem [1 ]
机构：
[1] Ege Univ, Izmir, Turkey
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：172 / 172
页数：1
相关论文
共 50 条
  • [41] A study of pegylated liposomal doxorubicin in platinum-refractory epithelial ovarian cancer
    Wilailak, S
    Linasmita, V
    ONCOLOGY, 2004, 67 (3-4) : 183 - 186
  • [42] EARLY CA-125 RESPONSE PATTERN IN PATIENTS WITH RECURRENT OVARIAN CANCER TREATED WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD)
    Oaknin, A.
    Barretina, P.
    Jimenez, L.
    Perez, X.
    Velasco, M.
    Alsina, M.
    Pardo, B.
    Brunet, J.
    Germa, J. R.
    Beltran, M.
    ANNALS OF ONCOLOGY, 2008, 19 : 215 - 215
  • [43] Relationship between serum hormone levels and pharmacokinetics (PK) of PEGylated liposomal doxorubicin (PLD) in patients with refractory ovarian cancer
    Kumar, Parag
    Caron, Whitney P.
    Song, Gina
    Gallagher, Katie
    Clarke-Pearson, Daniel L.
    Brewster, Wendy R.
    Van Le, Linda
    Bae-Jump, Victoria
    Gehrig, Paola A.
    Zamboni, William C.
    CANCER RESEARCH, 2012, 72
  • [44] Safety analysis of trabectedin in combination with pegylated liposomal doxorubicin (PLD) vs PLD alone in ovarian cancer patients 65 years of age and older
    Vergote, I.
    Vermorken, J.
    Pujade-Lauraine, E.
    Monk, B.
    Lisyanskaya, A.
    Rolski, J.
    Vasanthan, S.
    Santabarbara, P.
    Bayever, E.
    Poveda, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 458 - 458
  • [45] A RANDOMIZED PHASE III STUDY OF TRABECTEDIN WITH PEGYLATED LIPOSOMAL DOXORUBICIN (PLD) VERSUS PLD IN RELAPSED, RECURRENT OVARIAN CANCER (OC)
    Monk, B. J.
    Herzog, T.
    Kaye, S.
    Krasner, C. N.
    Vermorken, J.
    Muggia, F.
    Pujade-Lourraine, E.
    Renshaw, F. G.
    Lebedinsky, C.
    Poveda, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 2 - 2
  • [46] Carboplatin, pegylated liposomal Doxorubicin, and Bevacizumab in Ovarian Cancer
    Gappa, Birgit
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2020, 80 (08)
  • [47] Brain metastases in relapsed epithelial ovarian cancer after chemotherapy with pegylated liposomal doxorubicin
    Kasprowicz, Nikola Serena
    Fotopoulou, Christina
    Oskay-Oezcelik, Guelten
    El Khalfaoui, Khalid
    Boehmer, Dirk
    Sehouli, Jalid
    ANTICANCER RESEARCH, 2008, 28 (3B) : 1943 - 1946
  • [48] Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer
    Stebbing, J
    Gaya, A
    CANCER TREATMENT REVIEWS, 2002, 28 (02) : 121 - 125
  • [49] Pegylated liposomal doxorubicin/carboplatin combination in ovarian cancer, progressing on single-agent pegylated liposomal doxorubicin
    Grenader, Tal
    Rosengarten, Ora
    Isacson, Rut
    Plotkin, Yevgeni
    Gabizon, Alberto
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2012, 3 (10): : 137 - 141
  • [50] Relationship Between Complement Factors and CC Chemokines and the Pharmacokinetics (PK) and Pharmacodynamics (PD) of PEGylated Liposomal Doxorubicin (PLD) in Patients with Refractory Epithelial Ovarian Cancer (EOC)
    Song, G.
    Moore, S.
    Tarrant, T.
    Dobrovolskaia, M.
    Barrow, D.
    Kumar, P.
    Newman, S.
    Bae-Jump, V.
    Gehrig, P.
    Zamboni, W.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : 39 - 40
12345